Ownership history in Calydon Capital · 10 quarters on record
This page tracks every 13F SEC filing in which Calydon Capital reported a position in Abbott Laboratories (ABT). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q3 | REDUCED | 1,902 | -2,971 | -61.0% | 0.04% | $255K | $132.67 |
| 2025 Q2 | ADDED | 4,873 | +3,132 | +179.9% | 0.06% | $663K | $134.12 |
| 2025 Q1 | REDUCED | 1,741 | -97 | -5.3% | 0.04% | $231K | $130.21 |
| 2024 Q4 | REDUCED | 1,838 | -821 | -30.9% | 0.04% | $208K | $110.45 |
| 2022 Q4 | ADDED | 2,659 | +468 | +21.4% | 0.07% | $292K | $103.05 |
| 2022 Q3 | REDUCED | 2,191 | -777 | -26.2% | 0.06% | $212K | $90.39 |
| 2022 Q2 | ADDED | 2,968 | +1,138 | +62.2% | 0.08% | $322K | $101.05 |
| 2022 Q1 | REDUCED | 1,830 | -518 | -22.1% | 0.05% | $217K | $109.64 |
| 2021 Q4 | ADDED | 2,348 | +250 | +11.9% | 0.08% | $330K | $129.92 |
| 2021 Q3 | INITIATED | 2,098 | — | — | 0.07% | $248K | $108.62 |
As of 2025 Q4 — sorted by position size